PIONEER III trial results demonstrate safety and efficacy of HT Supreme stent

923
HT Supreme

Sinomed has announced that the PIONEER III clinical trial results for its HT Supreme drug-eluting stent (DES) system has been published in Circulation. Investigators demonstrated equivalence in safety and effectiveness between the HT Supreme and best-in-class DES.

“This trial was performed in the USA, Europe and Japan and the enrolled patients reflect a broad spectrum of disease treated. The HT Supreme performed very well and showed results non-inferior to the current market leading stent,” said Andreas Baumbach from St. Bartholomew’s Hospital, London, UK, and European co-principal investigator. “I am now looking forward to see whether the novel design of the stent platform and drug delivery system will result in superior outcomes in future long-term follow-up out to five years.”

The PIONEER III study enrolled 1,629 patients from centres in Belgium, Canada, France, Germany, Japan, Netherlands, Spain, Switzerland, UK, and USA. This tri-continent trial had a primary composite endpoint of target lesion failure (TLF) at one-year.  The TLF outcomes showed that the HT Supreme met the non-inferiority endpoint at 5.4% compared to 5.1% from the control arm (p=0.002) of Xience (Abbott) and Promus (Boston Scientific) devices.

A grouped analysis of secondary endpoints showed a numerically better result for HT Supreme in cardiac death or target-vessel myocardial infarction (TV MI) with 3.5% in the HT Supreme arm compared to 4.6% in the control arm (p=0.27).  Lower late stent thrombosis data (0.1% compared to 0.4%, p=0.22) also suggested exceptional safety for the HT Supreme.

“PIONEER III is the cornerstone of our extensive, international clinical trial program and I am very grateful for the support we have had from investigators around the world,” said Jianhua Sun, chairman and chief executive officer of Sinomed. “Now is a very exciting time for us as we are in the early stage of product launch where we are putting our clinical learnings towards real-life clinical experience.“

A powered, landmark TLF analysis evaluating the healing superiority of HT Supreme between one and five years is ongoing. Data from this trial will be submitted to the US Food and Drug Administration (FDA) for approval in the USA and the and Pharmaceuticals and Medical Devices Agency (PMDA) for approval in Japan.

The HT Supreme represents a novel class of stents that highlights the importance of early, timely healing, Sinomed says in a press release. Through patented designs and proprietary processes, the HT Supreme is tailored to help patients accelerate their wound-healing process and restore their naturally protective vessel function, the company adds. The HT Supreme was launched this summer in Europe and China.


LEAVE A REPLY

Please enter your comment!
Please enter your name here